EPISODE · Apr 12, 2023 · 14 MIN
Let's Talk Relapsed/Refractory Chronic Lymphocytic Leukemia: Expert Perspectives on Reversible BTK Inhibitors
from Keeping Current CME
Did you know studies have shown that noncovalent BTK inhibitors are efficacious in patients with covalent BTK inhibitor-pretreated CLL? Credit available for this activity expires: 4/12/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/990418?ecd=bdc_podcast_libsyn_mscpedu
Embed this episode
NOW PLAYING
Let's Talk Relapsed/Refractory Chronic Lymphocytic Leukemia: Expert Perspectives on Reversible BTK Inhibitors
0:00
14:33
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Keeping Current CME?
This episode is 14 minutes long.
When was this Keeping Current CME episode published?
This episode was published on April 12, 2023.
Can I download this Keeping Current CME episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!